Related Experiment Video

Updated: Aug 17, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

[Effect of spironolactone on left ventricular remodeling in patients with acute myocardial infarction]

Qi Dong1, Kun-shen Liu, Hong-bin Liu

  • 1Department of Cardiology, The First Hospital of Hebei Medical University, Shijiazhuang 050031, China. hsylyf@tom.com

Zhonghua Xin Xue Guan Bing Za Zhi
|June 4, 2005
PubMed

Insights

Spironolactone effectively prevents left ventricular remodeling in anterior myocardial infarction patients by reducing fibrosis and dilation. However, it showed no significant benefit for inferior myocardial infarction patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Context:

  • Left ventricular remodeling (LVRM) is a significant complication following acute myocardial infarction (AMI).
  • Spironolactone, a mineralocorticoid receptor antagonist, has shown potential in managing cardiovascular conditions.
  • Understanding the specific effects of spironolactone on LVRM based on infarct location is crucial for targeted therapy.

Purpose:

  • To investigate the efficacy of spironolactone in preventing left ventricular remodeling (LVRM) in patients who have experienced acute myocardial infarction (AMI).
  • To assess the impact of spironolactone on myocardial fibrosis, left ventricular function, and volume in AMI patients.

Summary:

  • This multicenter, randomized controlled study involved 88 AMI patients, comparing spironolactone plus routine treatment against routine treatment alone.
  • In anterior MI patients, spironolactone significantly reduced serum PIIINP and BNP levels, indicating decreased myocardial fibrosis, and resulted in smaller left ventricular end-diastolic and end-systolic dimensions.
  • No significant differences in fibrosis markers or left ventricular remodeling parameters were observed in inferior MI patients treated with spironolactone compared to the control group.

Impact:

  • Spironolactone demonstrates a significant benefit in inhibiting myocardial fibrosis and preventing left ventricular dilation in anterior myocardial infarction, thereby preventing LVRM.
  • The findings suggest that the therapeutic effect of spironolactone on LVRM is dependent on the location of the myocardial infarction.
  • This research provides valuable insights for tailoring pharmacological interventions for post-MI patients based on infarct characteristics.
Abstract

More Related Videos

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...